Market Overview

UPDATE: Benchmark Raises Price Target on BioClinica to $8


According to Benchmark, BioClinica (NASDAQ: BIOC) price target is raised to $8.

Benchmark said that it hosted an investor event at BioClinica's eClinical software headquarters in Audubon, PA on January 13. “We are increasing our price target to $8.00, from $7.00, to reflect a 20x multiple of our unchanged $0.40 EPS forecast this year.”

BioClinica closed on Friday at $4.77.


Related Articles (BIOC)

View Comments and Join the Discussion!

Posted-In: BenchmarkAnalyst Color Price Target Analyst Ratings

Latest Ratings

XPOJP MorganMaintains84.0
UPSJP MorganMaintains113.0
UNPJP MorganMaintains163.0
NSCJP MorganMaintains189.0
MCHPJP MorganMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at